British billionaire Mike Platt hops on board a London startup looking at drug discovery from a different angle
Back in 2016, upon graduating with his PhD from University College London, Giuseppe Mazza and his professor Massimo Pinzani spun out Engitix to understand disease from a slightly different angle. Now they’re ready to build out a pipeline — and they’ve piqued the interest of British billionaire hedge fund manager Mike Platt.
Engitix unveiled a $54 million Series A round early Wednesday morning, on top of a new collaboration deal with Italian biopharma company Dompé. The focus is on the human extracellular matrix (ECM) — the networks of proteins and carbohydrates that pass between cells, communicating and assuring the whole system functions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.